Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.74M Sell
24,800
-30,800
-55% -$1.59M ﹤0.01% 3126
2026
Q1
$2.82M Buy
55,600
+43,600
+363% +$2.03M ﹤0.01% 2484
2025
Q4
$354K Buy
+12,000
New +$326K ﹤0.01% 3505
2022
Q1
Sell
-69,700
Closed -$17.7M 3716
2021
Q4
$17.7M Buy
69,700
+3,000
+4% +$877K 0.04% 531
2021
Q3
$25.7M Sell
66,700
-19,400
-23% -$7.15M 0.06% 374
2021
Q2
$20.2M Sell
86,100
-82,900
-49% -$14.8M 0.05% 489
2021
Q1
$22.1M Buy
+169,000
New +$24.5M 0.06% 390

Other funds holding MRNA

John Overdeck's MRNA Position: Q2 2026 in Review

John Overdeck reduced its Moderna (MRNA) stake by 21% in Q2 2026, selling an estimated $97.9M and leaving 7,193,530 shares worth $504M. The position accounts for 0.36% of the portfolio, ranked #45.

John Overdeck first reported a position in MRNA in Q2 2019 and has held it in 19 quarters since. 775 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • John Overdeck held 7,193,530 shares of Moderna worth $504M as of Q2 2026.
  • John Overdeck sold 1,892,874 Moderna shares in Q2 2026, an estimated $97.9M.
  • Moderna made up 0.36% of John Overdeck's portfolio in Q2 2026, its #45 holding.
  • John Overdeck first reported a position in Moderna in Q2 2019 and has held it in 19 quarters since.
  • 775 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.